Citius Pharmaceuticals, Inc. (CTXR) financial statements (2020 and earlier)

Company profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
9/30/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments89301 0
Cash and cash equivalents89301 0
Receivables 1     
Prepaid expense00010 
Total current assets:810311 0
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment0000   
Intangible assets, net (including goodwill)22220
Goodwill2222   
Intangible assets, net (excluding goodwill)    0  
Other undisclosed noncurrent assets18191919   
Total noncurrent assets:212121210  
TOTAL ASSETS:293124221 0
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4323100
Accounts payable321110 
Accrued liabilities00110 0
Employee-related liabilities1111   
Interest and dividends payable0000   
Debt000  00
Derivative instruments and hedges, liabilities   21  
Due to related parties  000  
Other undisclosed current liabilities   1 00
Total current liabilities:5325100
Noncurrent Liabilities
Total liabilities:5325100
Stockholders' equity
Stockholders' equity attributable to parent, including:24282217(1)(0)(0)
Common stock0000000
Additional paid in capital8068503480 
Accumulated deficit(56)(40)(28)(17)(9)  
Other undisclosed stockholders' equity attributable to parent     (0)(0)
Total stockholders' equity:24282217(1)(0)(0)
TOTAL LIABILITIES AND EQUITY:293124221 0

Income statement (P&L) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
9/30/2012
Revenues01     
Other operating income 1     
Cost of revenue
(Cost of Goods and Services Sold)
 (0)(0)    
Gross profit:01(0)    
Operating expenses(16)(14)(10)(7)(3)(0)(0)
Other undisclosed operating income (loss)(0)(1)0    
Operating loss:(16)(14)(10)(7)(3)(0)(0)
Nonoperating income (expense)01(0)(1)0  
Investment income, nonoperating0      
Debt instrument, convertible, beneficial conversion feature 22    
Other nonoperating income   00  
Interest and debt expense(0)0(1)(0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(16)(12)(11)(8)(3)(0)(0)
Other undisclosed income (loss) from continuing operations before income taxes31(0)100  
Income (loss) before gain (loss) on sale of properties:16(13)(10)(8)(3)(0)(0)
Other undisclosed net loss(31)      
Net loss available to common stockholders, diluted:(16)(13)(10)(8)(3)(0)(0)

Comprehensive Income ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
9/30/2012
Net loss:(16)(13)(10)(8)(3)(0)(0)
Comprehensive loss, net of tax, attributable to parent:(16)(13)(10)(8)(3)(0)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: